NewAmsterdam Pharma (NAMS) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.

Does the MarketBeat Community favor ASND or NAMS?

Ascendis Pharma A/S received 421 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.30% of users gave NewAmsterdam Pharma an outperform vote while only 66.82% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
Ascendis Pharma A/S	Outperform Votes 447 66.82%	Underperform Votes 222 33.18%
NewAmsterdam Pharma	Outperform Votes 26 96.30%	Underperform Votes 1 3.70%

Do institutionals and insiders believe in ASND or NAMS?

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Do analysts prefer ASND or NAMS?

Ascendis Pharma A/S presently has a consensus target price of $204.64, indicating a potential upside of 29.29%. NewAmsterdam Pharma has a consensus target price of $43.33, indicating a potential upside of 92.08%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
NewAmsterdam Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable valuation and earnings, ASND or NAMS?

NewAmsterdam Pharma has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$363.64M	26.42	-$409.12M	-$7.10	-22.29
NewAmsterdam Pharma	$45.56M	54.38	-$176.94M	-$2.60	-8.68

Which has more risk and volatility, ASND or NAMS?

Ascendis Pharma A/S has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500.

Is ASND or NAMS more profitable?

NewAmsterdam Pharma has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -104.54%.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-104.54%	N/A	-39.23%
NewAmsterdam Pharma	N/A	N/A	N/A

Does the media refer more to ASND or NAMS?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 4 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.21 beat Ascendis Pharma A/S's score of 1.02 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NewAmsterdam Pharma beats Ascendis Pharma A/S on 11 of the 17 factors compared between the two stocks.